1. Feldman BA. Rhabdomyosarcoma of the head and neck. Laryngoscope. 1982; 92:424–440.
2. La Quaglia MP, Heller G, Ghavimi F, Casper ES, Vlamis V, Hajdu S, et al. The effect of age at diagnosis on outcome in rhabdomyosarcoma. Cancer. 1994; 73:109–117.
3. Tateishi U, Hosono A, Makimoto A, Nakamoto Y, Kaneta T, Fukuda H, et al. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma. Ann Nucl Med. 2009; 23:155–161.
4. Klem ML, Grewal RK, Wexler LH, Schöder H, Meyers PA, Wolden SL. PET for staging in rhabdomyosarcoma: an evaluation of PET as an adjunct to current staging tools. J Pediatr Hematol Oncol. 2007; 29:9–14.
5. Peng F, Rabkin G, Muzik O. Use of 2-deoxy-2-[F-18]-fluoro-D-glucose positron emission tomography to monitor therapeutic response by rhabdomyosarcoma in children: report of a retrospective case study. Clin Nucl Med. 2006; 31:394–397.
6. Iagaru A, Goris ML. Rhabdomyosarcoma diffusely metastatic to the bone marrow: suspicious findings on 99mTc-MDP bone scintigraphy confirmed by (18)F-18 FDG PET/CT and bone marrow biopsy. Eur J Nucl Med Mol Imaging. 2008; 35:1746.
7. Seshadri N, Wright P, Balan KK. Rhabdomyosarcoma with widespread bone marrow infiltration: beneficial management role of F-18 FDG PET. Clin Nucl Med. 2007; 32:787–789.
8. Hagiwara A, Inoue Y, Nakayama T, Yamato K, Nemoto Y, Shakudo M, et al. The "botryoid sign": a characteristic feature of rhabdomyosarcomas in the head and neck. Neuroradiology. 2001; 43:331–335.
9. Enzinger FM, Weiss SW. Soft tissue tumors. 3rd ed. St Louis: Mosby;1995. p. 539–577.
10. Ihara T, Okamura D, Takahashi N, Kohri M, Kayano H, Tamaru J, et al. Alveolar rhabdomyosarcoma mimicking nasal lymphoma at the initial presentation. J Clin Exp Hematop. 2008; 48:61–64.